Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor

被引:232
|
作者
Scheuermann, Thomas H. [1 ,2 ]
Tomchick, Diana R. [1 ]
Machius, Mischa [1 ]
Guo, Yan [1 ]
Bruick, Richard K. [1 ]
Gardner, Kevin H. [1 ,2 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
internal cavity; NMR; X-ray crystallography; hypoxia; protein-ligand interactions; ARYL-HYDROCARBON RECEPTOR; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; PROTEIN; OXYGEN; DIMERIZATION; FAMILY; ALPHA; NMR; HETERODIMERIZATION;
D O I
10.1073/pnas.0808092106
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The hypoxia-inducible factor (HIF) basic helix-loop-helix Per-aryl hydrocarbon receptor nuclear translocator (ARNT)-Sim (bHLH-PAS) transcription factors are master regulators of the conserved molecular mechanism by which metazoans sense and respond to reductions in local oxygen concentrations. In humans, HIF is critically important for the sustained growth and metastasis of solid tumors. Here, we describe crystal structures of the heterodimer formed by the C-terminal PAS domains from the HIF2 alpha and ARNT subunits of the HIF2 transcription factor, both in the absence and presence of an artificial ligand. Unexpectedly, the HIF2 alpha PAS-B domain contains a large internal cavity that accommodates ligands identified from a small-molecule screen. Binding one of these ligands to HIF2 alpha PAS-B modulates the affinity of the HIF2 alpha:ARNT PAS-B heterodimer in vitro. Given the essential role of PAS domains in forming active HIF heterodimers, these results suggest a presently uncharacterized ligand-mediated mechanism for regulating HIF2 activity in endogenous and clinical settings.
引用
收藏
页码:450 / 455
页数:6
相关论文
共 50 条
  • [1] Principles of Ligand Binding within a Completely Buried Cavity in HIF2α PAS-B
    Key, Jason
    Scheuermann, Thomas H.
    Anderson, Peter C.
    Daggett, Valerie
    Gardner, Kevin H.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (48) : 17647 - 17654
  • [2] Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
    Rogers, Jamie L.
    Bayeh, Liela
    Scheuermann, Thomas H.
    Longgood, Jamie
    Key, Jason
    Naidoo, Jacinth
    Melito, Lisa
    Shokri, Cameron
    Frantz, Doug E.
    Bruick, Richard K.
    Gardner, Kevin H.
    MacMillan, John B.
    Tambar, Uttam K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (04) : 1739 - 1747
  • [3] The HIF2α puzzle
    Meera Swami
    Nature Reviews Cancer, 2010, 10 : 603 - 603
  • [4] Protein Dynamics of the HIF-2α PAS-B Domain upon Heterodimerization and Ligand Binding
    Masetti, Matteo
    Falchi, Federico
    Recanatini, Maurizio
    PLOS ONE, 2014, 9 (04):
  • [5] HYPOXIA The HIF2α puzzle
    Swami, Meera
    NATURE REVIEWS CANCER, 2010, 10 (09) : 603 - 603
  • [6] Upstream Stimulatory Factor 2 and Hypoxia-Inducible Factor 2α (HIF2α) Cooperatively Activate HIF2 Target Genes during Hypoxia
    Pawlus, Matthew R.
    Wang, Liyi
    Ware, Katie
    Hu, Cheng-Jun
    MOLECULAR AND CELLULAR BIOLOGY, 2012, 32 (22) : 4595 - 4610
  • [7] The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia
    Magliulo, Daniela
    Simoni, Matilde
    Caserta, Carolina
    Fracassi, Cristina
    Belluschi, Serena
    Giannetti, Kety
    Pini, Raffaella
    Zapparoli, Ettore
    Beretta, Stefano
    Ugge, Martina
    Draghi, Eleonora
    Rossari, Federico
    Coltella, Nadia
    Tresoldi, Cristina
    Morelli, Marco J.
    Di Micco, Raffaella
    Gentner, Bernhard
    Vago, Luca
    Bernardi, Rosa
    EMBO MOLECULAR MEDICINE, 2023, 15 (11)
  • [8] Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
    Arnaiz, Esther
    Miar, Ana
    Bridges, Esther
    Prasad, Naveen
    Hatch, Stephanie B.
    Ebner, Daniel
    Lawrie, Charles H.
    Harris, Adrian L.
    BMC CANCER, 2021, 21 (01)
  • [9] Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
    Esther Arnaiz
    Ana Miar
    Esther Bridges
    Naveen Prasad
    Stephanie B. Hatch
    Daniel Ebner
    Charles H. Lawrie
    Adrian L. Harris
    BMC Cancer, 21
  • [10] HIF2α central player in osteoarthritis
    Alexandra Flemming
    Nature Reviews Drug Discovery, 2010, 9 : 517 - 517